Imatinib Mesylate (Gleevec; STI571) Monotherapy Is Ineffective in Suppressing Human Anaplastic Thyroid Carcinoma Cell Growth in Vitro

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 5, 2004, Pages 2127-2135

  Dziba, Joshua M ^b   Ain, Kenneth B ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE; STEM CELL FACTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TUMOR; HUMAN; HUMAN CELL; IN VIVO STUDY; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THYROID CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GENES, ABL; HUMANS; ONCOGENE PROTEINS; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; THYROID NEOPLASMS; TYROSINE;

EID: 2442423952     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031734     Document Type: Article

References (49)

1. 2003 Gleevec approved for first-line treatment of CML. FDA Consum 37:5
2. 2002 New Gleevec treatment approved. FDA Consum 36:6
3. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS 2001 Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421-1423
4. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD 2001 Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056
5. Courtneidge SA 2003 Cancer: escape from inhibition. Nature 422:827-828
6. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M 2001 Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042
7. le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti-Passerini C 1999 In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 91:163-168
8. May TS 2003 Gleevec: tailoring to fit. Drug Discov Today 8:188-189
9. Podtcheko A, Ohtsuru A, Tsuda S, Namba H, Saenko V, Nakashima M, Mitsutake N, Kanda S, Kurebayashi J, Yamashita S 2003 The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 88:1889-1896
10. Ain KB 1998 Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8:715-726
11. Dziba JM, Marcinek R, Venkataraman G, Robinson JA, Ain KB 2002 Combretastatin a4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 12: 1063-1070
12. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV 2000 Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96:1070-1079
13. Lozzio CB, Lozzio BB 1975 Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45:321-334
14. Deininger MW, Goldman JM, Lydon N, Melo JV 1997 The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90:3691-3698
15. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ 2000 Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 96:3195-3199
16. Palyi I, Peter I, Daubner D, Vincze B, Lorincz I 1993 Establishment, characterization and drug sensitivity of a new anaplastic thyroid carcinoma cell line (BHT-101). Virchows Arch B Cell Pathol Incl Mol Pathol 63:263-269
17. Heldin NE, Westermark B 1991 The molecular biology of the human anaplastic thyroid carcinoma cell. Thyroidology 3:127-131
18. Farooqui T, Kelley T, Coggeshall KM, Rampersaud AA, Yates AJ 1999 GM1 inhibits early signaling events mediated by PDGF receptor in cultured human glioma cells. Anticancer Res 19:5007-5013
19. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR 1988 Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589-601
20. Mosmann T 1983 Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63
21. Durkin WJ, Ghanta VK, Balch CM, Davis DW, Hiramoto RN 1979 A methodological approach to the prediction of anticancer drug effect in humans. Cancer Res 39:402-407
22. Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S, Edmands S, Kirk J, Lee A, Kessler P, Schoch G, Buckner CD, Sullivan KM, Appelbaum FR, Thomas ED 1995 Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 85:2632-2638
23. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G 1985 Structural organization of the bcr gene and its role in the Ph′ translocation. Nature 315:758-761
24. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M 1991 Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757-766
25. Herbert DJ, Bagwell B, Munson ME, Hunsberger BC Examination of some DNA guidelines using simulation data. Topsham, ME: Verity Software House, Inc. Publication: http://www.vsh.com/Publication/S_phase_Study.pdf
26. Hunsberger B, Bagwell CB, Herbert D, Bray C, Langweiler M 2003 Effects of resolution reduction on data analysis. Cytometry 53A:103-111
27. Shankey TV, Rabinovitch PS, Bagwell B, Bauer KD, Duque RE, Hedley DW, Mayall BH, Wheeless L, Cox C 1993 Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry 14:472-477
28. 2002 Protein binding of imatinib in humans. In: Imatinib mesylate investigator's brochure, 5th ed. East Hanover, NJ: Novartis Oncology
29. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB 1996 Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100-104
30. McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ, Bar-Eli M 2002 Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 8:3584-3591
31. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J 2000 Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938-1942
32. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB 2000 Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145
33. Chen H, Isozaki K, Kinoshita K, Ohashi A, Shinomura Y, Matsuzawa Y, Kitamura Y, Hirota S 2003 Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors. Int J Cancer 105:130-135
34. Holyoake DT 2001 Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br J Haematol 113:11-23
35. Frasca F, Vigneri P, Vella V, Vigneri R, Wang JY 2001 Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to hepatocyte growth factor. Oncogene 20:3845-3856
36. Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J, Superti-Furga G 2003 A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112:845-857
37. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J 2003 Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112:859-871
38. Dorey K, Engen JR, Kretzschmar J, Wilm M, Neubauer G, Schindler T, Superti-Furga G 2001 Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase. Oncogene 20:8075-8084
39. Mitsiades CS, Sykoutri D, McMullan C, Poulaki V, Mitsiades N 2003 Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab 88:5043-5044; author reply 5044
40. Natali PG, Berlingieri MT, Nicotra MR, Fusco A, Santoro E, Bigotti A, Vecchio G 1995 Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Res 55:1787-1791
41. Heldin NE, Cvejic D, Smeds S, Westermark B 1991 Coexpression of functionally active receptors for thyrotropin and platelet-derived growth factor in human thyroid carcinoma cells. Endocrinology 129:2187-2193
42. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, Ostman A 2002 Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476-5484
43. Heldin CH, Westermark B, Wasteson A 1981 Specific receptors for platelet-derived growth factor on cells derived from connective tissue and glia. Proc Natl Acad Sci USA 78:3664-3668
44. Heldin NE, Gustavsson B, Claesson-Welsh L, Hammacher A, Mark J, Heldin CH, Westermark B 1988 Aberrant expression of receptors for platelet-derived growth factor in an anaplastic thyroid carcinoma cell line. Proc Natl Acad Sci USA 85:9302-9306
45. Forsberg K, Valyi-Nagy I, Heldin CH, Herlyn M, Westermark B 1993 Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci USA 90:393-397
46. Pietras K, Stumm M, Hubert M, Buchdunger E, Rubin K, Heldin CH, McSheehy P, Wartmann M, Ostman A 2003 STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 9:3779-3787
47. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184
48. Ain KB, Tofiq S, Taylor KD 1996 Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 81:3650-3653
49. Viaggi M, Dagrosa MA, Belli C, Larripa I, Gangitano D, Cabrini R, Pisarev MA, Juvenal G 2003 A new animal model for human undifferentiated thyroid carcinoma. Thyroid 13:529-536